Cyclacel Pharmaceuticals Inc Financial Flexibility Index
Cyclacel Pharmaceuticals Inc financial flexibility index. Cyclacel Pharmaceuticals Inc (CYCC) has a Financial Flexibility Index of -1.37x as of June 2025. Free cash flow of $-1.06K (operating CF $-1.06K minus capex $0.00) represents -1% of total liabilities ($770.00). See Cyclacel Pharmaceuticals Inc (CYCC) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Cyclacel Pharmaceuticals Inc (2003–2024)
Financial flexibility index of Cyclacel Pharmaceuticals Inc from 2003 to 2024. Historical Financial Flexibility Index trend for Cyclacel Pharmaceuticals Inc across 22 annual periods. Check Cyclacel Pharmaceuticals Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Cyclacel Pharmaceuticals Inc Financial Flexibility Index by Year (2003–2024)
Cyclacel Pharmaceuticals Inc financial flexibility index by year from 2003 to 2024. Year-by-year free cash flow to debt coverage for Cyclacel Pharmaceuticals Inc. For the full cash flow conversion analysis, see cash flow conversion of Cyclacel Pharmaceuticals Inc.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.27x | $-7.99 Million | $-7.99 Million | $6.27 Million | ▲ +35.1% |
| 2023 | -1.96x | $-16.11 Million | $-16.11 Million | $8.20 Million | ▲ +28.1% |
| 2022 | -2.73x | $-20.82 Million | $-20.83 Million | $7.62 Million | ▲ +19.6% |
| 2021 | -3.40x | $-18.51 Million | $-18.54 Million | $5.44 Million | ▼ -53.7% |
| 2020 | -2.21x | $-7.84 Million | $-7.93 Million | $3.54 Million | ▲ +15.3% |
| 2019 | -2.61x | $-9.44 Million | $-9.45 Million | $3.61 Million | ▼ -78.5% |
| 2018 | -1.46x | $-6.66 Million | $-6.70 Million | $4.55 Million | ▲ +16.9% |
| 2017 | -1.76x | $-7.47 Million | $-7.48 Million | $4.24 Million | ▲ +5.7% |
| 2016 | -1.87x | $-10.08 Million | $-10.08 Million | $5.39 Million | ▲ +23.2% |
| 2015 | -2.43x | $-14.43 Million | $-14.46 Million | $5.93 Million | ▼ -1.8% |
| 2014 | -2.39x | $-18.39 Million | $-18.70 Million | $7.70 Million | ▲ +0.4% |
| 2013 | -2.40x | $-17.99 Million | $-18.20 Million | $7.50 Million | ▼ -86.2% |
| 2012 | -1.29x | $-12.03 Million | $-12.04 Million | $9.34 Million | ▲ +40.1% |
| 2011 | -2.15x | $-13.97 Million | $-13.98 Million | $6.50 Million | ▲ +12.4% |
| 2010 | -2.45x | $-16.04 Million | $-16.04 Million | $6.54 Million | ▼ -58.8% |
| 2009 | -1.55x | $-15.18 Million | $-15.19 Million | $9.82 Million | ▲ +46.0% |
| 2008 | -2.86x | $-29.54 Million | $-29.91 Million | $10.31 Million | ▼ -140.5% |
| 2007 | -1.19x | $-21.37 Million | $-23.14 Million | $17.94 Million | ▲ +42.9% |
| 2006 | -2.08x | $-19.50 Million | $-20.17 Million | $9.36 Million | ▲ +30.8% |
| 2005 | -3.01x | $-20.61 Million | $-21.51 Million | $6.84 Million | ▼ -107.9% |
| 2004 | -1.45x | $-16.64 Million | $-21.09 Million | $11.48 Million | ▼ -733.3% |
| 2003 | -0.17x | $-14.49 Million | $-15.49 Million | $83.34 Million | — |